Relay Therapeutics Inc Ordinary Shares RLAY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $7.06
- Day Range
- $7.14–7.60
- 52-Week Range
- $5.70–12.14
- Bid/Ask
- $7.08 / $8.00
- Market Cap
- $1.20 Bil
- Volume/Avg
- 3 / 1.9 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 26.85
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 304
- Website
- https://www.relaytx.com
Comparables
Valuation
|
Metric
|
RLAY
|
TNGX
|
ZNTL
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.45 | 3.18 | 0.69 |
Price/Sales | 26.85 | 18.14 | 6.45 |
Price/Cash Flow | — | — | — |
Price/Earnings
RLAY
TNGX
ZNTL
Financial Strength
|
Metric
|
RLAY
|
TNGX
|
ZNTL
|
|---|---|---|---|
Quick Ratio | 15.28 | 7.34 | 0.00 |
Current Ratio | 15.64 | 7.49 | 6.59 |
Interest Coverage | — | — | — |
Quick Ratio
RLAY
TNGX
ZNTL
Profitability
|
Metric
|
RLAY
|
TNGX
|
ZNTL
|
|---|---|---|---|
Return on Assets (Normalized) | −28.22% | −24.41% | −27.12% |
Return on Equity (Normalized) | −32.40% | −38.87% | −33.35% |
Return on Invested Capital (Normalized) | −34.47% | −35.94% | −36.67% |
Return on Assets
RLAY
TNGX
ZNTL
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Zqmmfymtc | Bsqsw | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nbvrqrkrz | Rktcsgk | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zhhlckhy | Gxxlsq | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Znycmnvc | Lvlzh | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Vqtltbb | Yqqr | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Yqhhptczm | Cjwfj | $28.0 Bil | |||
| Moderna Inc
MRNA
| Djwvmkxlz | Vdydt | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Jnrbxbqk | Clcw | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Nqbwnnj | Bqdtlwr | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Fffvjsjwsg | Hlnslvn | $12.6 Bil |
United States